Evidence map›Paper›PMID 33007104›Full record

SynthesisAddiction (Abingdon, England)2021

The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).

David Simons, Lion Shahab, Jamie Brown, Olga Perski

3 registry-linked trialsOpen access · hybridAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 248 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed, 6 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04915781 completednot on this map

Tobacco Use and Incidence of SARS-CoV-2 Infection in the Finnish General Population

TypeobservationalSponsorFinnish Institute for Health and WelfareRan2017 to 2021Enrolled60,872ConditionsSARS-CoV-2 Infection, Covid19ArmsNot applicable, this is an observational study
NCT05321433 completednot on this mapstarted 2022, after this paper: background citation

The Association Between Tobacco Use and COVID-19 Infection and Adverse Outcomes in Three Nordic Countries: a Pooled Analysis

Typeobservational_patient_registrySponsorKarolinska InstitutetRan2022 to 2023Enrolled757,585ConditionsCOVID-19, Respiratory Tract Infections, Infections, Pneumonia, Viral
NCT05479383 unknown statusnot on this map

Tobacco Use and Uptake of COVID-19 Vaccinations in Finland: a General Population Study

TypeobservationalSponsorFinnish Institute for Health and WelfareRan2017 to 2023Enrolled42,935ConditionsCOVID-19, Smoking, Tobacco Use, Vaccination RefusalArmsNot applicable, this is an observational study
3 · Its place in the literature

Who cites it

248 citing papers in PubMed, 6 syntheses or guidelines pooled it, 392 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The role of smoking in COVID-19 progression: a comprehensive meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Impact of Smoking on Household SARS-CoV-2 Transmission.Healthcare (Basel, Switzerland) · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

David SimonsCentre for Emerging, Endemic and Exotic Diseases, Royal Veterinary College, London, UK.ORCID 0000-0001-9655-1656
Lion ShahabDepartment of Behavioural Science and Health, University College London, London, UK.ORCID 0000-0003-4033-442X
Jamie BrownDepartment of Behavioural Science and Health, University College London, London, UK.ORCID 0000-0002-2797-5428
Olga PerskiDepartment of Behavioural Science and Health, University College London, London, UK.ORCID 0000-0003-3285-3174
University College London · GBRoyal Veterinary College · GB

Funding

Cancer Research UK 22962Cancer Research UK C1417/A22962Medical Research Council MR/S037519/1
6 · The paper itself

Abstract

aimsTo estimate the association of smoking status with rates of (i) infection, (ii) hospitalization, (iii) disease severity and (iv) mortality from SARS-CoV-2/COVID-19 disease.

designLiving rapid review of observational and experimental studies with random-effects hierarchical Bayesian meta-analyses. Published articles and pre-prints were identified via MEDLINE and medRxiv.

settingCommunity or hospital, no restrictions on location.

participantsAdults who received a SARS-CoV-2 test or a COVID-19 diagnosis. MEASUREMENTS: Outcomes were SARS-CoV-2 infection, hospitalization, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. 'good', 'fair' and 'poor').

findingsVersion 7 (searches up to 25 August 2020) included 233 studies with 32 'good' and 'fair' quality studies included in meta-analyses. Fifty-seven studies (24.5%) reported current, former and never smoking status. Recorded smoking prevalence among people with COVID-19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-CoV-2 infection [relative risk (RR) = 0.74, 95% credible interval (CrI) = 0.58-0.93, τ = 0.41]. Data for former smokers were inconclusive (RR = 1.05, 95% CrI = 0.95-1.17, τ = 0.17), but favoured there being no important association (21% probability of RR ≥ 1.1). Former compared with never smokers were at somewhat increased risk of hospitalization (RR = 1.20, CrI = 1.03-1.44, τ = 0.17), greater disease severity (RR = 1.52, CrI = 1.13-2.07, τ = 0.29) and mortality (RR = 1.39, 95% CrI = 1.09-1.87, τ = 0.27). Data for current smokers were inconclusive (RR = 1.06, CrI = 0.82-1.35, τ = 0.27; RR = 1.25, CrI = 0.85-1.93, τ = 0.34; RR = 1.22, 95% CrI = 0.78-1.94, τ = 0.49, respectively), but favoured there being no important associations with hospitalization and mortality (35% and 70% probability of RR ≥ 1.1, respectively) and a small but important association with disease severity (79% probability of RR ≥ 1.1).

conclusionsCompared with never smokers, current smokers appear to be at reduced risk of SARS-CoV-2 infection, while former smokers appear to be at increased risk of hospitalization, increased disease severity and mortality from COVID-19. However, it is uncertain whether these associations are causal.

Indexed as

SARS-CoV-2Bayes TheoremCOVID-19HospitalizationHumansMortalityPrevalenceRiskSeverity of Illness IndexSmokingCOVID-19e-cigaretteshospitalizationinfectionliving reviewmortalitynicotine replacement therapySARS-CoV-2smokingtobacco

Identifiers

PMID33007104
PMCPMC7590402
OpenAlexW3083147446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.